Audentes Therapeutics Priced, Nasdaq: BOLD

Preclinical biotech developing gene therapies for rare diseases.

Industry: Health Care

Latest Trade: $27.47 0.00 (0.0%)

First Day Return: +0.9%

Return from IPO: +83.1%

Industry: Health Care

We are a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. We believe that gene therapy has powerful potential to treat these diseases through delivery of a functional copy of the affected gene to cells, resulting in production of the normal protein. We have built a compelling portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy, or XLMTM, AT342 for the treatment of Crigler-Najjar Syndrome, or Crigler-Najjar, AT982 for the treatment of Pompe disease and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia, or CASQ2-CPVT. We plan to submit Investigational New Drug applications, or INDs, or Clinical Trial Authorisations, or CTAs, for AT982 in the third quarter of 2016, for AT342 in the fourth quarter of 2016 and for AT132 in the first quarter of 2017, and expect to have preliminary data from all three programs in the second half of 2017. We maintain full global rights to all of our product candidates.
more less
IPO News for Audentes Therapeutics
more
IPO Data
IPO File Date 01/04/2016
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
IPO Data
IPO Date 07/19/2016
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
Underwriters
more
Company Data
Headquarters San Francisco, CA
Founded 2012
Employees 75
Website www.audentestx.com